Until 2018, Egypt had the highest prevalence of hepatitis C virus (HCV) infection globally, affecting approximately 7% of the population. Despite efforts in diagnosis and treatment since 2006, nearly 2 million individuals with chronic HCV infection had yet to be diagnosed as of early 2018. In December, 2018, a mass HCV screening campaign for adolescents aged 15–18 years was initiated. Among 3 024 325 adolescents screened, the HCV antibody seroprevalence was 11 477 (0·38%), of whom 8187 (78·7%) were HCV RNA-positive. Sustained virological response 12 weeks after completion of treatment (SVR12) was attained by 7327 (99·6%) adolescents with a fixed-dose combination of generic ledipasvir 90 mg plus sofosbuvir 400 mg. Although mass screening in this age group might not be regularly adopted by many health systems and its cost-effectiveness might be lower than the screening of adults and high-risk groups (eg, patients on haemodialysis, people who inject drugs), breaking the chain of transmission in younger populations should lead to a reduction in HCV incidence and complications, and hasten the elimination of the disease.

直到 2018 年，埃及的丙型肝炎病毒 (HCV) 感染率在全球最高，影响了大约 7% 的人口。尽管自2006年以来大力开展诊治工作，但截至2018年初，仍有近200万慢性HCV感染者未确诊。2018年12月，启动了针对15-18岁青少年的大规模HCV筛查活动。筛查青少年3 024 325人，HCV抗体阳性率为11 477人（0·38%），其中HCV RNA阳性8187人（78·7%）。7327 名 (99·6%) 青少年接受通用 ledipasvir 90 mg 加 sofosbuvir 400 mg 的固定剂量组合治疗后 12 周获得持续病毒学应答 (SVR12)。